Royal Bank of Canada
AMLX icon

Royal Bank of Canada’s Amylyx Pharmaceuticals AMLX Stock Holding History

Royal Bank of Canada’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Buy
14,649
+2,266
+18% +$35K ﹤0.01% 4798
2026
Q1 		$172K Sell
12,383
-3,260
-21% -$45.9K ﹤0.01% 4793
2025
Q4 		$188K Sell
15,643
-77,369
-83% -$1.05M ﹤0.01% 4806
2025
Q3 		$1.26M Buy
93,012
+80,879
+667% +$761K ﹤0.01% 3783
2025
Q2 		$78K Buy
12,133
+283
+2% +$1.38K ﹤0.01% 5733
2025
Q1 		$42K Sell
11,850
-24
-0.2% -$85 ﹤0.01% 5632
2024
Q4 		$45K Buy
11,874
+24
+0.2% +$113 ﹤0.01% 5741
2024
Q3 		$38K Sell
11,850
-5,281
-31% -$11.9K ﹤0.01% 5821
2024
Q2 		$32K Buy
17,131
+15,779
+1,167% +$30.6K ﹤0.01% 5856
2024
Q1 		$3K Sell
1,352
-14,803
-92% -$194K ﹤0.01% 6567
2023
Q4 		$237K Buy
16,155
+8,060
+100% +$124K ﹤0.01% 4956
2023
Q3 		$148K Buy
8,095
+4,021
+99% +$85K ﹤0.01% 5069
2023
Q2 		$88K Buy
4,074
+446
+12% +$12K ﹤0.01% 5426
2023
Q1 		$107K Sell
3,628
-3,049
-46% -$106K ﹤0.01% 5126
2022
Q4 		$247K Buy
6,677
+5,304
+386% +$188K ﹤0.01% 4691
2022
Q3 		$38K Buy
1,373
+365
+36% +$9.11K ﹤0.01% 5870
2022
Q2 		$19K Sell
1,008
-3,286
-77% -$39K ﹤0.01% 6129
2022
Q1 		$56K Buy
+4,294
New +$97K ﹤0.01% 6004

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Royal Bank of Canada's AMLX Position: Q2 2026 in Review

Royal Bank of Canada increased its Amylyx Pharmaceuticals (AMLX) stake by 18% in Q2 2026, buying an estimated $35K and bringing the position to 14,649 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #4798.

Royal Bank of Canada first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.26M in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Royal Bank of Canada held 14,649 shares of Amylyx Pharmaceuticals worth $263K as of Q2 2026.
  • Royal Bank of Canada bought 2,266 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $35K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4798 holding.
  • Royal Bank of Canada first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Royal Bank of Canada's Amylyx Pharmaceuticals position peaked at $1.26M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.